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Objectives: The mortality of ruptured infrarenal
abdominal aortic aneurysms (rAAA) is as high as 70%.
Loss of consciousness and systolic blood pressure on
presentation of less than 80 mmHg are the most important
predictors of mortality after emergent open repair (OR).
Endovascular repair of abdominal aortic aneurysm
(EVAR) has reduced short-term operative mortality and
morbidity for elective abdominal aortic aneurysm repair
and many have advocated for wider application of EVAR
for rAAA. The objective of this study is to compare our
experience with OR and EVAR management of rAAA.
Methods: A retrospective review of all rAAA present-
ing to our institution from 2000 to 2011 was performed.
Patients were grouped based on the surgical approach
taken (OR or EVAR). Demographics,co-morbidities,
mortality and morbidity rates were compared.Statistical
analyses were conducted with Stata, version 12.
Results: 145 patients presented with rAAA over the
study period. 22% of patients underwent EVAR, 64%
underwent OR and 14% declined repair. A preoperative
computed tomography scan was available in 99 patients.
Only one patient (0.69%) required conversion to OR
from EVAR.There was no statistical difference in 30-day
(EVAR, 25%; OR, 40%; P ¼ .12) and 1-year (EVAR,
31.25%; OR, 45.74%; P ¼ .5)mortality rates.Morbidity
was 78% in the EVAR and 75% in OR group. Respiratory
failure and abdominal compartment syndrome were the
major complications in the patients undergoing EVAR,
while respiratory and renal failure were most common in
the patients undergoing OR.
Conclusions: In contrast to recently published series,
this review shows no difference in clinical outcome
between EVAR and OR in the treatment of rAAA. The
comorbidities and the clinical status of the patient upon
arrival to the hospital remain the most important prog-
nostic predictors of morbidity and mortality. Until
randomized trial data are available, these results lead us
to pursue EVAR for rAAA in stable patients with favorable
anatomy rather than a more universal approach.
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Objectives: Vascular related complications negatively
impact nearly 1/3 of patients undergoing transcatheter
aortic valve replacement (TAVR). This study evaluates
the utilization of vascular adjunctive procedures and bail-
outs during TAVR in the “real-world scenarios.”
Methods: In 2012, we evaluated aortoiliac morphology
and outcomes of 103 consecutive patients that underwent
TAVR (n¼ 53; 51%) with the structural heart team inclusive
of cardiologists and cardiac & vascular surgeons, and TEVAR
(n ¼ 50; 49%). Patients were evaluated on an intent-to-treat
basis, and data on all adjunctive vascular procedures & bail-
outs was prospectively collected.
Results: The 30-day mortality of TAVR (4%) and
TEVAR (2%) was comparable. TAVR patents were older
(mean age, 80 yrs vs 70 yrs; P < .01), and had a higher inci-
dence of aortoiliac signiﬁcant circumferential calciﬁcations
(14% vs 6%). Hostile aortoiliac access that would have
excluded patients form TAVR was noted in 21 (42%)
patients. Compared to TEVAR, TAVR patients had a signif-
icantly higher incidence of vascular complications (18% vs
6%; P < .05), and the need for secondary vascular proce-
dures (48% vs 2%; P < .01) including misplaced aortic valve
retrieval (n¼ 3; 6%), aortoiliac interventions (n¼ 10; 20%),
and iliofemoral reconstructions (n ¼ 11, 22%).
Conclusions: When compared to TEVAR, TAVR
patients are older, have more complex aortoiliac access,
have a higher incidence of vascular complications, and
have a greater need for adjunctive secondary vascular proce-
dures. Regardless, vascular surgeon’s primary involvement
limits the vascular morbidity and mortality, and expands
TAVR indications for use to over 40% of inoperable and
high-risk patients that are currently denied treatment.
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Type II Endoleak: An Ambiguous and Unpredictable
Marker of Worse Outcome After EVAR
